CTOs on the Move

Evelo Therapeutics

www.evelotx.com

 
Evelo Therapeutics is the latest breakthrough microbiome company from Flagship VentureLabs, the innovation foundry of Flagship Ventures.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.evelotx.com
  • 620 Memorial Drive Suite 200 West
    Cambridge, MA USA
  • Phone: 617.870.1335

Executives

Name Title Contact Details

Funding

Evelo Therapeutics raised $35M on 11/04/2015

Similar Companies

United Biomedical

United Biomedical, Inc. (UBI) is an international bio/pharmaceutical firm with cutting edge technology utilizing reverse genomics and synthetic peptide chemistry, coupled with traditional pharmaceutical and therapeutic delivery systems. The company has

Seattle Biomedical Research Institute

Seattle Biomedical Research Institute is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accelerated Technologies Partners

Accelerated Technologies Partners is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dallas Employment Services

Dallas Employment Services , Inc. is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amarantus

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.   Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard").